Mounjaro Guidelines: What People Already on It Need to Know

Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist supplied as a pre-filled, once-weekly injectable pen. Guidelines — including those developed by bodies such as the National Institute for Health and Care Excellence (NICE) in the UK — set out which adults may be considered for the medicine and under what conditions. These criteria typically consider factors such as body mass index (BMI), the presence of weight-related health conditions, and the requirement for ongoing clinical supervision. Your prescriber will have assessed your suitability before prescribing, and will continue to review your progress throughout.

How titration is structured

Guidelines consistently describe a titration approach: treatment begins at the lowest available dose (2.5 mg) and is increased gradually — usually at intervals decided by the prescriber — through available strengths up to a maintenance dose. The pace and endpoint of that titration is an individual, clinical decision. No guideline instructs patients to change their own dose; adjustments are always made in partnership with a prescriber. If you have questions about where you are in your titration, that conversation belongs with your prescriber or doctor.

Monitoring and reporting

Guidelines also emphasise ongoing monitoring: regular check-ins to assess weight, tolerability, and any side effects. Mounjaro carries a black triangle (▼) designation in the UK, meaning it is subject to additional monitoring. Any suspected side effects should be reported to a healthcare professional and to your national reporting scheme (such as the UK's Yellow Card scheme, or the equivalent programme in your country). You can read more about the specific criteria and thresholds in the NICE guidance on Mounjaro, or explore how Mounjaro prescribing works in practice.

Wegovy guidelines — the broader picture

Wegovy (semaglutide), a GLP-1 receptor agonist, operates under a similar guideline framework — prescription-only, titrated from a low starting dose, and supervised by a prescriber. Where this page refers to Mounjaro guidelines, many of the same principles apply to Wegovy. If you are prescribed Wegovy, the same emphasis on prescriber-led titration, regular monitoring, and side-effect reporting holds true. The broader Mounjaro overview covers how these medicines sit within the wider GLP-1 landscape.

One of the most practical ways to stay aligned with the guidelines your prescriber follows is to keep a clear, consistent record of your journey. GLP Trackr's dose logging feature lets you record every injection — the date, dose strength, and which pen you used — so you always have an accurate history to bring to your next appointment. This matters because guidelines place regular review at the centre of treatment: the more clearly you can show your prescriber how your doses, side effects, and progress have tracked over time, the more productive that conversation can be.

The app's side-effect tracker complements this: log symptoms such as nausea, fatigue, or digestive changes as they happen, and the app surfaces patterns over time. Rather than trying to recall how you felt three weeks ago, you arrive at your review with a timestamped log. The built-in doctor report feature can then pull this together into a summary you can share directly.

GLP Trackr also includes dose reminders, so a weekly injection is never accidentally missed — keeping you consistent with the schedule your prescriber has set. Every decision about your dose, however, remains with your prescriber or doctor, not the app. GLP Trackr records and organises your data; it does not advise on clinical matters. If anything in your experience feels severe, persistent, or out of the ordinary, contact your healthcare professional promptly.

Ready to bring more structure to your treatment journey? Download GLP Trackr on the App Store or Google Play — your first 7 days are free.